![]() |
Zolbetuximab is given as an intravenous infusion to patients with advanced gastric cancer in combination with chemotherapy. Photo Credit: Hiroshi Tsubono |
Gastric cancer is the fifth most commonly diagnosed malignancy worldwide. It ranks a sad third in cancer-related causes of death. The reason for this is late diagnosis coupled with rapid spread of tumor cells in the body. In an international clinical study co-chaired by investigators from Leipzig University’s Faculty of Medicine, researchers investigated a substance that is expected to prolong the survival of patients and also established a new clinically relevant biomarker. The results have been published in the renowned journal “The Lancet”.
“The results of the study are important for cancer research. They show that patients with gastric cancer who have been treated with zolbetuximab live longer. The progression of the tumor disease is delayed and overall survival of patients is improved. We expect that the study will lead to the approval of this drug in Europe and as a result also in Germany. This is an important step for those affected by this serious and often fatal cancer,” said Professor Florian Lordick, director of the University Cancer Center Leipzig. The experienced oncologist helped to design the recently published study at the international level and ensured that German patients were able to participate.